Physician profile
Margaret H Hoffmeyer
NPI 1215962568
$1,579.57
in general payments reported to CMS, 2019-2025
15 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $291 · 2021: $376 · 2022: $273 · 2023: $47.97 · 2024: $66.77 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $256.46 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $763.09 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $206.34 | 2020-2022 | |
| Astellas Pharma US INC | $122.33 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $109.04 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $71.26 | 2019-2021 | |
| Lilly USA, LLC | $66.06 | 2019-2023 | Jardiance |
| Esperion Therapeutics, INC. | $50.74 | 2024-2025 | Nexletol |
| Amarin Pharma, INC. | $33.98 | 2019 | |
| Abbott Laboratories | $29.66 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $27.54 | 2021-2022 | |
| Horizon Therapeutics Plc | $26.30 | 2019-2021 | |
| Abbvie INC. | $25.59 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.89 | 2019-2021 | |
| Mylan Specialty L.P. | $12.88 | 2019 | |
| Amgen INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Hoffmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.